Ligand validation:6HL3

NAD: NICOTINAMIDE-ADENINE-DINUCLEOTIDE

NAD is a Ligand Of Interest in 6HL3 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6HL3_NAD_B_503	63%	67%	0.16	0.955	0.57	0.71	-	2	5	0	100%	1
6HL3_NAD_D_503	60%	67%	0.159	0.945	0.58	0.7	-	2	5	0	100%	1
6HLA_NAD_B_503	87%	63%	0.098	0.971	0.62	0.78	-	2	4	0	100%	1
6HLM_NAD_D_503	69%	63%	0.123	0.936	0.65	0.76	-	1	3	0	100%	1
6HLI_NAD_B_502	27%	64%	0.255	0.903	0.59	0.78	-	1	6	0	100%	0.7045
4URF_NAD_A_1249	100%	44%	0.034	0.995	0.96	1.2	2	4	0	0	100%	1
2C5A_NAD_B_1374	100%	23%	0.039	0.992	1.34	1.84	6	7	1	0	100%	1
1HET_NAD_A_402	100%	10%	0.043	0.994	2.25	2.1	9	8	0	0	100%	0.9068
2JHF_NAD_B_403	100%	16%	0.04	0.99	2.08	1.62	11	5	2	0	100%	1
1HEU_NAD_B_402	100%	7%	0.043	0.993	2.5	2.41	13	11	0	0	100%	0.8886

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.